CAS 677010-34-3
:Motavizumab
Description:
Motavizumab is a monoclonal antibody designed for therapeutic use, specifically targeting the respiratory syncytial virus (RSV). It is a humanized IgG1 antibody that binds to the F protein of RSV, thereby inhibiting the virus's ability to infect host cells. This characteristic makes it a potential treatment for RSV infections, particularly in high-risk populations such as infants and immunocompromised individuals. Motavizumab is notable for its high affinity and specificity for the RSV F protein, which enhances its efficacy in neutralizing the virus. The antibody is administered via injection and has been studied for its safety and effectiveness in clinical trials. Its development reflects ongoing efforts to improve respiratory viral infection management, particularly in vulnerable patient groups. As with many monoclonal antibodies, potential side effects may include allergic reactions or infusion-related reactions, necessitating careful monitoring during administration. Overall, Motavizumab represents a significant advancement in the therapeutic landscape for RSV.
Formula:Unspecified
Synonyms:- Numax
- Motavizumab
- Immunoglobulin G1, anti-(respiratory syncytial virus glycoprotein F) (human-mouse monoclonal MEDI-524 γ1-chain), disulfide with human-mouse monoclonal MEDI-524 κ-chain, dimer
- Motovizumab
- MEDI 524
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Found 2 products.
Motavizumab
CAS:Motavizumab (MEDI-524) is a neutralizing antibody against RSV, altering the cytokine response induced by RSV in a mouse model.Purity:>95%Color and Shape:Liquid
